Baker McKenzie has advised Bristol Myers Squibb on the transfer of Juno Therapeutics GmbH to TQ Therapeutics GmbH ("TQx") through a share acquisition agreement. The strategic acquisition is intended to accelerate the development of innovative cell therapies. The financial terms of the agreement were not disclosed.
Juno Therapeutics GmbH ("Juno GmbH") was a German subsidiary of Juno Therapeutics, Inc., a wholly owned subsidiary of Bristol Myers Squibb, a global biopharmaceutical company dedicated to discovering, developing and delivering innovative medicines that help patients overcome serious diseases.
TQ Therapeutics GmbH is a biotechnology company based in Planegg/Munich, Germany, dedicated to the advancement of cell therapies through innovative technologies. TQx is transforming the traditional production of cell therapies towards a decentralized, scalable, fast and highly automated cost-efficient platform. The acquisition of Juno GmbH will increase TQx's capabilities, expanding access to intellectual property and license agreements that will support the development of the company's potentially transformative cell processing platform.
Baker McKenzie's Corporate/M&A team regularly advises on national and international transactions. Most recently, Baker McKenzie advised MAT Holdings on the sale of its subsidiaries to AEQUITA and Evonik Industries AG on a virtual general meeting, Sunoco on the acquisition of TanQuid Group; Georg Fischer on the acquisition of VAG Group; AURELIUS on the acquisition of Teijin Automotive Technologies; Centric Software on the acquisition of Contentserv Group; Fagron Group on the acquisition of Euro OTC & Audor Pharma GmbH; Berlin Packaging, a portfolio company of Oak Hill Capital Partners and Canada Pension Plan Investment Board, on its acquisition of RIXIUS AG; Instalco on its investment in FABRI AG; AURELIUS on its acquisition of the Savoury Division of What's Cooking; UBE Corporation on its acquisition of the Urethane Systems business of LANXESS and Grundfos on its acquisition of the C&I business of Culligan.
Legal advisor to Bristol Myers Squibb: Baker McKenzie
Lead: Corporate/M&A: Dr. Tino Marz (Partner, Munich)
Team: Corporate/M&A: Julia Braun (Partner, Munich), Holger Engelkamp (Partner, Berlin), Oren Livne (Partner, New York), Stefanie Tesch (Senior Associate, Munich), Dr. Julia Rossié (Senior Associate, Munich), Erik Kuhn (Associate, Munich)
Employment: Dr. Felix Diehl (Partner, Frankfurt)
Pensions: Dr. Anna Verena Böhm (Counsel, Frankfurt)
Commercial & Trade: Joachim Fröhlich (Counsel, Frankfurt)
IP: Patrick Wilkening (Partner, Düsseldorf), Felix Osiander (Associate, Frankfurt)
About Baker McKenzie
Complex business challenges require an integrated response across different markets, sectors, and areas of law. Baker McKenzie's client solutions provide seamless advice, underpinned by deep practice and sector expertise, as well as first-rate local market knowledge from more than 70 offices globally. Baker McKenzie works alongside clients to deliver solutions for a connected world.
Juno Therapeutics GmbH ("Juno GmbH") was a German subsidiary of Juno Therapeutics, Inc., a wholly owned subsidiary of Bristol Myers Squibb, a global biopharmaceutical company dedicated to discovering, developing and delivering innovative medicines that help patients overcome serious diseases.
TQ Therapeutics GmbH is a biotechnology company based in Planegg/Munich, Germany, dedicated to the advancement of cell therapies through innovative technologies. TQx is transforming the traditional production of cell therapies towards a decentralized, scalable, fast and highly automated cost-efficient platform. The acquisition of Juno GmbH will increase TQx's capabilities, expanding access to intellectual property and license agreements that will support the development of the company's potentially transformative cell processing platform.
Baker McKenzie's Corporate/M&A team regularly advises on national and international transactions. Most recently, Baker McKenzie advised MAT Holdings on the sale of its subsidiaries to AEQUITA and Evonik Industries AG on a virtual general meeting, Sunoco on the acquisition of TanQuid Group; Georg Fischer on the acquisition of VAG Group; AURELIUS on the acquisition of Teijin Automotive Technologies; Centric Software on the acquisition of Contentserv Group; Fagron Group on the acquisition of Euro OTC & Audor Pharma GmbH; Berlin Packaging, a portfolio company of Oak Hill Capital Partners and Canada Pension Plan Investment Board, on its acquisition of RIXIUS AG; Instalco on its investment in FABRI AG; AURELIUS on its acquisition of the Savoury Division of What's Cooking; UBE Corporation on its acquisition of the Urethane Systems business of LANXESS and Grundfos on its acquisition of the C&I business of Culligan.
Legal advisor to Bristol Myers Squibb: Baker McKenzie
Lead: Corporate/M&A: Dr. Tino Marz (Partner, Munich)
Team: Corporate/M&A: Julia Braun (Partner, Munich), Holger Engelkamp (Partner, Berlin), Oren Livne (Partner, New York), Stefanie Tesch (Senior Associate, Munich), Dr. Julia Rossié (Senior Associate, Munich), Erik Kuhn (Associate, Munich)
Employment: Dr. Felix Diehl (Partner, Frankfurt)
Pensions: Dr. Anna Verena Böhm (Counsel, Frankfurt)
Commercial & Trade: Joachim Fröhlich (Counsel, Frankfurt)
IP: Patrick Wilkening (Partner, Düsseldorf), Felix Osiander (Associate, Frankfurt)
About Baker McKenzie
Complex business challenges require an integrated response across different markets, sectors, and areas of law. Baker McKenzie's client solutions provide seamless advice, underpinned by deep practice and sector expertise, as well as first-rate local market knowledge from more than 70 offices globally. Baker McKenzie works alongside clients to deliver solutions for a connected world.
Explore Our Newsroom